Siam Pukkato/Dreamstime
Covid 19 Vaccine Vial Doctor Gloves Syringe © Siam Pukkato Dreamstime

Phase 3 Trials Begin for Novavax Vaccine in US, Mexico

Dec. 29, 2020
Two other vaccines that have conducted Phase 3 trials, those from Johnson & Johnson and AstraZeneca/Oxford, are expected soon to seek emergency authorization for distribution in the U.S.

Clinical trials to determine the safety and efficacy of a Covid-19 vaccine candidate from American biotech company Novavax have begun in the United States and Mexico, the US National Institutes of Health (NIH) announced Monday. 

A similar Phase 3 trial for the same vaccine, called NVX-CoV2373, is also under way in the United Kingdom, where about 15,000 volunteers have been recruited.  

In the US and Mexico, the new trials will include around 30,000 volunteers over the age of 18. 

Two-thirds of the participants will receive the vaccine and one-third a placebo. None of them will know, for the duration of the trial, what was in the injection they received. 

"The launch of this study -- the fifth investigational COVID-19 vaccine candidate to be tested in a Phase 3 trial in the United States -- demonstrates our resolve to end the pandemic through development of multiple safe and effective vaccines," said leading US immunologist Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. 

The goal is that at least 25% of the participants in the US and Mexico trials should be aged 65 and over, the statement said. 

Emphasis will also be placed on recruiting people who are more exposed to Covid-19 -- African-Americans and Hispanics in particular -- or who present with underlying health conditions that put them at higher risk, such as obesity or diabetes.

The vaccine is taken in two doses three weeks apart. It can be stored between two and eight degrees Celsius (35 and 46 degrees Fahrenheit) -- much warmer temperatures than already approved vaccines from Pfizer/BioNTech and Moderna, meaning it could be more easily distributed.

The Pfizer and Moderna vaccines are based on a new technology, messenger RNA, while the Novavax vaccine is a recombinant protein vaccine. 

The coronavirus has spikes (viral proteins) on its surface that come into contact with cells it infects. These proteins can be reproduced and presented to the immune system so that it can later recognize them and react if it is actually infected. 

Two other vaccines that have conducted Phase 3 trials, those from Johnson & Johnson and AstraZeneca/Oxford, are expected soon to seek emergency authorization for distribution in the US, the country most affected by the pandemic in absolute numbers worldwide.

Copyright Agence France-Presse, 2020

Popular Sponsored Recommendations

Get ready for CLOUD 9: Nine reasons to move to the Microsoft Cloud

Jan. 24, 2024
With pioneering AI (Copilot, built on OpenAI) and best-in-class low code development tools (Power Platform), the Microsoft Cloud has no equal. Learn a whole lot more in in “Moving...

Five Tips for Choosing the Right AMR to Improve Worker Productivity

Jan. 24, 2024
Here are five top tips to consider before selecting an AMR to increase productivity for your enterprise.

How to Build a Predictive Maintenance Program: Lessons Learned from LSB Industries’ Success

Dec. 21, 2023
Register today and join this webinar to gain insight on best practices for setting up a predictive maintenance program from industry experts.

6 Ways Manufacturers Can Use GenAI Today

Feb. 1, 2024
Hear six compelling use cases where generative AI is making a significant impact in augmenting frontline workers and transforming operations. Learn how GenAI Assistants and smart...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!